Your browser is no longer supported. Please, upgrade your browser.
Ironwood Pharmaceuticals, Inc.
Index- P/E14.36 EPS (ttm)0.66 Insider Own0.90% Shs Outstand160.08M Perf Week-5.39%
Market Cap1.49B Forward P/E9.06 EPS next Y1.05 Insider Trans-3.10% Shs Float155.36M Perf Month-8.32%
Income106.20M PEG- EPS next Q0.20 Inst Own- Short Float11.09% Perf Quarter-18.94%
Sales389.50M P/S3.83 EPS this Y74.90% Inst Trans-0.17% Short Ratio11.10 Perf Half Y-8.93%
Book/sh0.39 P/B24.31 EPS next Y8.96% ROA22.40% Target Price11.17 Perf Year-15.92%
Cash/sh2.31 P/C4.11 EPS next 5Y- ROE- 52W Range7.99 - 12.84 Perf YTD-16.77%
Dividend- P/FCF8.93 EPS past 5Y21.60% ROI28.50% 52W High-27.10% Beta1.35
Dividend %- Quick Ratio- Sales past 5Y21.10% Gross Margin99.20% 52W Low17.15% ATR0.47
Employees232 Current Ratio15.40 Sales Q/Q-7.60% Oper. Margin36.70% RSI (14)33.78 Volatility4.34% 4.73%
OptionableYes Debt/Eq0.00 EPS Q/Q-12.50% Profit Margin27.30% Rel Volume0.63 Prev Close9.48
ShortableYes LT Debt/Eq6.87 EarningsFeb 17 BMO Payout0.00% Avg Volume1.55M Price9.36
Recom2.80 SMA20-7.24% SMA50-14.38% SMA200-10.35% Volume426,394 Change-1.27%
Sep-30-20Downgrade Wells Fargo Overweight → Equal Weight $14 → $9
Jun-17-20Initiated Northland Capital Outperform $14
Jul-10-19Resumed Credit Suisse Neutral
Mar-27-19Upgrade Morgan Stanley Underweight → Equal-Weight
Feb-25-19Upgrade H.C. Wainwright Sell → Neutral $14
Jan-24-19Upgrade JP Morgan Underweight → Neutral
Nov-07-18Downgrade JP Morgan Neutral → Underweight
Nov-07-18Downgrade Credit Suisse Outperform → Neutral
Jul-23-18Initiated H.C. Wainwright Sell $12.50
May-09-18Downgrade Morgan Stanley Equal-Weight → Underweight
Jan-05-18Downgrade BofA/Merrill Buy → Underperform
Dec-06-17Downgrade Mizuho Buy → Neutral $16
Jul-21-17Downgrade JP Morgan Overweight → Neutral
May-03-17Initiated Wells Fargo Outperform
Apr-07-17Reiterated Mizuho Buy $21 → $22
Feb-22-17Reiterated Barclays Equal Weight $13 → $16
Nov-04-16Reiterated Mizuho Buy $19 → $20
Oct-24-16Reiterated Wedbush Neutral $10 → $13
Oct-10-16Reiterated Mizuho Buy $24 → $19
Sep-27-16Reiterated WallachBeth Hold $15 → $17
Feb-19-21 04:01PM  
Feb-17-21 12:00PM  
Feb-10-21 12:31PM  
Feb-09-21 08:09AM  
Feb-08-21 04:01PM  
Feb-03-21 04:01PM  
Jan-05-21 07:30AM  
Dec-05-20 11:32AM  
Dec-04-20 08:44AM  
Dec-03-20 08:30AM  
Nov-30-20 01:39PM  
Nov-27-20 12:20PM  
Nov-07-20 12:31AM  
Nov-06-20 04:01PM  
Nov-05-20 07:05PM  
Oct-29-20 12:35PM  
Oct-22-20 04:01PM  
Sep-30-20 11:08AM  
Sep-29-20 08:55AM  
Sep-27-20 07:33AM  
Sep-14-20 10:55PM  
Sep-05-20 11:31AM  
Sep-02-20 04:00PM  
Aug-26-20 12:20PM  
Aug-07-20 02:52PM  
Aug-06-20 10:45AM  
Jul-30-20 12:33PM  
Jul-23-20 04:05PM  
Jul-21-20 07:00AM  
Jul-12-20 07:40PM  
Jun-08-20 02:51AM  
Jun-05-20 11:31AM  
Jun-03-20 09:56AM  
May-28-20 09:10AM  
May-27-20 08:51AM  
May-11-20 06:53AM  
May-07-20 10:00PM  
May-06-20 07:15PM  
Apr-29-20 12:34PM  
Apr-28-20 04:05PM  
Apr-16-20 04:05PM  
Apr-10-20 08:49AM  
Apr-07-20 03:32PM  
Mar-26-20 09:00AM  
Mar-14-20 11:30AM  
Feb-26-20 04:05PM  
Feb-25-20 04:05PM  
Feb-20-20 11:13AM  
Feb-14-20 09:50AM  
Feb-13-20 09:45AM  
Feb-10-20 12:38PM  
Feb-06-20 12:31PM  
Jan-30-20 04:05PM  
Jan-22-20 09:20AM  
Jan-06-20 08:00AM  
Jan-02-20 04:01PM  
Dec-31-19 08:58AM  
Dec-27-19 12:00PM  
Dec-26-19 09:00AM  
Dec-25-19 11:30AM  
Dec-23-19 08:33AM  
Dec-19-19 07:34PM  
Dec-18-19 09:23AM  
Dec-13-19 08:39AM  
Dec-10-19 09:15AM  
Dec-09-19 10:20AM  
Dec-03-19 08:51AM  
Nov-29-19 09:39AM  
Nov-27-19 08:21AM  
Nov-26-19 09:36AM  
Nov-22-19 09:48AM  
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the Canada and European Union; MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from abdominal pain associated with GI diseases; and IW 3718, a gastric retentive formulation of a bile acid sequestrant, which is in Phase III clinical trials for the treatment of GERD. Ironwood Pharmaceuticals, Inc. has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal (GI) conditions in North America, China, Hong Kong, Macau, and Japan, as well as a license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in Japan. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MCCOURT Thomas APresidentDec 14Option Exercise9.8999,988988,881421,720Dec 16 04:49 PM
MacDonald KellyChief Accounting OfficerDec 04Option Exercise9.125,63951,42898,680Dec 08 04:01 PM
MacDonald KellyChief Accounting OfficerDec 04Sale12.505,63970,48893,041Dec 08 04:01 PM
MacDonald KellyChief Accounting OfficerNov 11Option Exercise9.313,56133,15396,602Nov 13 04:02 PM
MacDonald KellyChief Accounting OfficerNov 11Sale11.753,56141,84293,041Nov 13 04:02 PM
Kilroy ConorSVP, GC & SecretaryNov 09Sale10.928369,129128,833Nov 10 04:09 PM
Consylman GinaSVP, CFO & TreasurerNov 09Sale10.921,41515,452269,699Nov 10 04:03 PM
Rickard JasonSVP, Chief Operating OfficerNov 09Sale10.923944,302235,382Nov 10 04:12 PM
MacDonald KellyChief Accounting OfficerNov 09Sale10.9292510,10193,041Nov 10 04:10 PM
MacDonald KellyChief Accounting OfficerNov 06Sale11.251,87221,06093,966Nov 10 04:10 PM
MacDonald KellyChief Accounting OfficerOct 08Sale10.5022,714238,49795,838Oct 13 04:03 PM
McHugh JulieDirectorSep 08Sale9.777,95077,672123,107Sep 09 06:26 PM
Rickard JasonSVP, Chief Operating OfficerAug 17Sale10.146896,986235,776Aug 19 04:05 PM
MacDonald KellyChief Accounting OfficerAug 17Sale10.145755,831118,552Aug 19 04:01 PM
OLANOFF LAWRENCE SDirectorJun 10Sale10.0611,350114,18168,629Jun 12 04:32 PM
Rickard JasonSVP, Chief Operating OfficerMay 11Sale10.355105,279234,580May 13 05:23 PM
MCCOURT Thomas APresidentMay 11Sale10.351,69717,564319,847May 13 05:22 PM
MacDonald KellyChief Accounting OfficerMay 11Sale10.351,15311,934118,147May 13 05:20 PM
Mallon MarkChief Executive OfficerMay 11Sale10.3523,206240,182501,280May 13 05:21 PM
Kilroy ConorSVP, GC & SecretaryMay 11Sale10.357167,411128,921May 13 05:19 PM